Immunome Inc’s recent filing unveils that its President and CEO SIEGALL CLAY B acquired Company’s shares for reported $1.16 million on Jan 31 ’25. In the deal valued at $7.75 per share,150,000 shares were bought. As a result of this transaction, SIEGALL CLAY B now holds 669,636 shares worth roughly $7.28 million.
Then, SIEGALL CLAY B bought 66,057 shares, generating $630,263 in total proceeds. Upon buying the shares at $9.54, the President and CEO now owns 485,693 shares.
Before that, SIEGALL CLAY B bought 33,943 shares. Immunome Inc shares valued at $331,918 were divested by the President and CEO at a price of $9.78 per share. As a result of the transaction, SIEGALL CLAY B now holds 519,636 shares, worth roughly $5.65 million.
Stephens initiated its Immunome Inc [IMNM] rating to an Overweight in a research note published on November 08, 2024; the price target was $30. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late May with a ‘”an Overweight”‘ rating. JP Morgan began covering IMNM with “an Overweight” recommendation on April 30, 2024. Guggenheim started covering the stock on April 15, 2024. It rated IMNM as “a Buy”.
Price Performance Review of IMNM
On Friday, Immunome Inc [NASDAQ:IMNM] saw its stock fall -4.90% to $10.87. Over the last five days, the stock has lost -1.45%. Immunome Inc shares have risen nearly 2.35% since the year began. Nevertheless, the stocks have fallen -52.96% over the past one year. While a 52-week high of $30.96 was reached on 02/05/25, a 52-week low of $8.97 was recorded on 01/29/25. SMA at 50 days reached $11.36, while 200 days put it at $13.09.
Levels Of Support And Resistance For IMNM Stock
The 24-hour chart illustrates a support level at 10.62, which if violated will result in even more drops to 10.37. On the upside, there is a resistance level at 11.33. A further resistance level may holdings at 11.80. The Relative Strength Index (RSI) on the 14-day chart is 51.44, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.96, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 42.72%. Stochastics %K at 73.31% indicates the stock is a holding.
How much short interest is there in Immunome Inc?
A steep rise in short interest was recorded in Immunome Inc stocks on 2025-01-15, growing by 1.74 million shares to a total of 10.54 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 8.8 million shares. There was a rise of 16.53%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 29, 2024 when Leerink Partners began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
